Status:
COMPLETED
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Lead Sponsor:
Shanghai YingLi Pharmaceutical Co. Ltd.
Conditions:
Small Lymphocytic Lymphoma
Lymphoplasmacytic Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological...
Eligibility Criteria
Inclusion
- histologically or cytologically confirmed relapse and/or refractory B cell hematologic malignancies(Excluding follicular lymphoma)
- prior treatment with ≥1 prior standard anti-tumor regimens and 2 courses of treatments at least
- eastern cooperative oncology group performance status of 0 to 2
- life expectancy of at least 3 months
- presence of \>1.5cm radiographically measurable lymphadenopathy or extranodal lymphoid malignancy, and legibility in two vertical directions
- acceptable organ functions
- discontinuation of all other antitumor therapies before the first drug dose administration
- for men and women of childbearing potential, willingness to abstain from sexual intercourse or employ an effective method of contraception during the study drug administration and follow-up six periods
- willingness and ability to provide written informed consent and to comply with the protocol requirements
Exclusion
- prior therapy with PI3K-delta inhibitors（except the intolerable subjects）
- the dosage of steroid hormone(predisone equivalent) was greater than 20mg/d, and lasted for more than 14 days
- medical condition of difficulty in swallowing, malabsorption, or other chronic gastrointestinal disease, or conditional that may hamper compliance and/or absorption of the investigational product
- concurrent drugs which maybe prolong the QT during the study period
- subjects with central nervous system metastasis
- Prior or current medical condition of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc
- active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- known history of chronic active hepatitis B infection, chronic active hepatitis C
- known history of immunodeficiency, including HIV positive test, other acquired or congenital immunodeficiency disorders, organ transplantation or allogeneic bone marrow transplantation
- autologous hematopoietic stem cell transplantation was received within 90 days before the first dose administration
- prior or ongoing heart disease, including: angina pectoris, clinically significant arrhythmia, myocardial infarction, heart failure, and any other heart disease judged by the researchers not eligible to the study
- pregnancy or breastfeeding
- prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant or impair the assessment of study results
- receiving granulocyte colony-stimulating factor(GCSF) or blood transfusion within seven days before screening
- history of a non-lymphoma malignancy except for adequately treated local basal cell carcinoma of the skin and cervical carcinoma in situ
- subjects, in the opinion of the the Investigator, who are unsuitable to participate in the study for any other reason.
Key Trial Info
Start Date :
June 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04279405
Start Date
June 15 2020
End Date
June 1 2023
Last Update
June 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, China